Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by HALL, M. R.
Right arrow Articles by EVERETT, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HALL, M. R.
Right arrow Articles by EVERETT, F. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1983 Oxford University Press

research-article

THE EFFECTS OF PROCAINE/ HAEMATOPORPHYRIN ON AGE-RELATED DECLINE: A DOUBLE-BLIND TRIAL

M. R. HALL, Professor of Geriatric Medicine, R. S. BRIGGS, Senior Lecturer in Geriatric Medicine, W. J. MacLENNAN, Senior Lecturer in Geriatric Medicine, D. MARCER, Senior Lecturer in Psychology, M. J. ROBINSON, Psychologist and F. M. EVERETT, Psychologist

Department of Geriatric Medicine Centre Block, Level E, Southampton General Hospital Southampton SO9 4XY
Department of Geriatric Medicine, Ninewells Hospital Dundee DE1 9SY
Department of Psychology Southampton University

A randomized, double-blind study of procaine/haematoporphyrin (KH3) has been carried out over two years in a selected population of healthy elderly subjects. The period of study exceeds 500 patient years. The trial population was weighted to contain a larger proportion of subjects aged over 75 years than a standard population; those receiving active KH3 had similar characteristics on entry to those receiving placebo.

Over the course of two years, KH3 was shown to be an active substance in that: (a) decrement in the consolidation of new learning was prevented in the treatment group (<1.0%, as against 38% in the placebo group); (b) the prevalence of incontinence increased significantly in the placebo group, but not in the active group (P<0.05); (c) there was a significant increase in grip strength in the active treatment group (+ 22%, P<0.01 v. placebo); (d) more adverse reactions were observed on treatment with KH3 (P<0.005).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.